The Lancet Haematology in conversation with

Jacob D Soumerai and Andrew D Zelenetz on the BOVen regimen for previously untreated patients with chronic lymphocytic leukaemia

The Lancet Haematology

Dr Jacob D Soumerai and Prof Andrew D Zelenetz discuss their phase 2 trial of the BOVen regimen and MRD-driven treatment discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma.

Read the full article:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00307-0/fulltext 

Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv